Humedix Co., Ltd. (200670.KQ)

KRW 39700.0

(-0.13%)

Operating Income Summary of Humedix Co., Ltd.

Humedix Co., Ltd.'s latest annual operating income in 2023 was 37.31 Billion KRW , up 47.03% from previous year.
Humedix Co., Ltd.'s latest quarterly operating income in 2024 Q1 was 10.58 Billion KRW , up 106.51% from previous quarter.
Humedix Co., Ltd. reported an annual operating income of 25.17 Billion KRW in 2022, up 64.04% from previous year.
Humedix Co., Ltd. reported an annual operating income of 15.34 Billion KRW in 2021, down -6.6% from previous year.
Humedix Co., Ltd. reported a quarterly operating income of 13.05 Billion KRW for 2024 Q2, up 23.37% from previous quarter.
Humedix Co., Ltd. reported a quarterly operating income of 9.25 Billion KRW for 2023 Q1, up 47.78% from previous quarter.

Annual Operating Income Chart of Humedix Co., Ltd. (2023 - 2015)

Historical Annual Operating Income of Humedix Co., Ltd. (2023 - 2015)

Year	Operating Income	Operating Income Growth
2023	37.31 Billion KRW	47.03%
2022	25.17 Billion KRW	64.04%
2021	15.34 Billion KRW	-6.6%
2020	16.43 Billion KRW	27.06%
2019	12.93 Billion KRW	20.97%
2018	10.69 Billion KRW	-9.34%
2017	11.79 Billion KRW	-8.14%
2016	12.83 Billion KRW	91281.72%
2015	14.04 Million KRW	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	10.58 Billion KRW	106.51%
2024 Q2	13.05 Billion KRW	23.37%
2023 Q1	9.25 Billion KRW	47.78%
2023 Q4	5.12 Billion KRW	-54.5%
2023 FY	37.01 Billion KRW	47.03%
2023 Q3	11.26 Billion KRW	-0.94%
2023 Q2	11.37 Billion KRW	22.81%
2022 Q1	4.12 Billion KRW	-9.99%
2022 Q4	6.26 Billion KRW	-17.43%
2022 FY	25.17 Billion KRW	64.04%
2022 Q3	7.58 Billion KRW	0.31%
2022 Q2	7.56 Billion KRW	83.51%
2021 Q3	2.94 Billion KRW	-13.87%
2021 Q1	4.5 Million KRW	-35.84%
2021 Q2	3.41 Billion KRW	75751.26%
2021 Q4	4.57 Billion KRW	55.58%
2021 FY	15.34 Billion KRW	-6.6%
2020 Q1	2.69 Million KRW	-32.1%
2020 FY	16.43 Billion KRW	27.06%
2020 Q4	7.02 Million KRW	96.34%
2020 Q3	3.57 Million KRW	6.78%
2020 Q2	3.34 Million KRW	24.32%
2019 Q3	3.55 Million KRW	15.75%
2019 Q2	3.07 Million KRW	14.65%
2019 Q1	2.67 Million KRW	-21.54%
2019 FY	12.93 Billion KRW	20.97%
2019 Q4	3.96 Million KRW	11.54%
2018 Q4	3.41 Million KRW	-1.02%
2018 FY	10.69 Billion KRW	-9.34%
2018 Q1	2.24 Million KRW	-21.13%
2018 Q2	1.57 Million KRW	-29.82%
2018 Q3	3.45 Million KRW	118.71%
2017 Q2	2.65 Million KRW	-6.17%
2017 FY	11.79 Billion KRW	-8.14%
2017 Q1	2.83 Million KRW	-18.9%
2017 Q4	2.85 Million KRW	-29.94%
2017 Q3	4.06 Million KRW	53.06%
2016 Q2	3.26 Million KRW	-5.74%
2016 Q1	3.46 Million KRW	0.0%
2016 FY	12.83 Billion KRW	91281.72%
2016 Q3	2.62 Million KRW	-19.64%
2016 Q4	3.49 Million KRW	33.24%
2015 FY	14.04 Million KRW	0.0%

Peer Operating Income Comparison of Humedix Co., Ltd.

Name	Operating Income	Operating Income Difference
HLB Pharmaceutical Co., Ltd	-19.54 Billion KRW	290.921%
CMG Pharmaceutical Co., Ltd.	5.72 Billion KRW	-551.682%
Celltrion Pharm, Inc.	36.07 Billion KRW	-3.436%
Huons Global Co., Ltd.	122.92 Billion KRW	69.648%
DongKook Pharmaceutical Co., Ltd.	66.87 Billion KRW	44.208%
Enzychem Lifesciences Corporation	-14.35 Billion KRW	359.889%
Boditech Med Inc.	33.44 Billion KRW	-11.563%
EuBiologics Co., Ltd.	7.69 Billion KRW	-384.602%
FutureChem Co.,Ltd	-8.4 Billion KRW	543.75%
Huons Co., Ltd.	59.79 Billion KRW	37.603%
BNC Korea Co., Ltd.	10.81 Billion KRW	-244.867%
AptaBio Therapeutics Inc.	-16.37 Billion KRW	327.868%